Cargando…

Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial

Background and Objectives: The purpose of this study was to compare the effect of topical bromfenac and dexamethasone on the intraocular concentration of interleukin 6 (IL-6) and incidence of pseudophakic cystoid macular oedema (PCME) after cataract surgery in patients with non-proliferative diabeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Jukić, Anđela, Kasalica Žužul, Rajka, Pavan, Josip, Lovrić, Mila, Kozmar, Ana, Plavec, Davor, Kuzman, Tomislav, Kalauz, Miro, Jukić, Tomislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694649/
https://www.ncbi.nlm.nih.gov/pubmed/36422204
http://dx.doi.org/10.3390/medicina58111667
_version_ 1784837854399037440
author Jukić, Anđela
Kasalica Žužul, Rajka
Pavan, Josip
Lovrić, Mila
Kozmar, Ana
Plavec, Davor
Kuzman, Tomislav
Kalauz, Miro
Jukić, Tomislav
author_facet Jukić, Anđela
Kasalica Žužul, Rajka
Pavan, Josip
Lovrić, Mila
Kozmar, Ana
Plavec, Davor
Kuzman, Tomislav
Kalauz, Miro
Jukić, Tomislav
author_sort Jukić, Anđela
collection PubMed
description Background and Objectives: The purpose of this study was to compare the effect of topical bromfenac and dexamethasone on the intraocular concentration of interleukin 6 (IL-6) and incidence of pseudophakic cystoid macular oedema (PCME) after cataract surgery in patients with non-proliferative diabetic retinopathy (NPDR). Materials and Methods: Ninety eyes of patients with mild-to-moderate NPDR that underwent phacoemulsification cataract surgery were divided into three groups. A detailed description of the clinical study protocol is described later in paper. In short, Group 1 received topical bromfenac (0.9 mg/mL), Group 2 dexamethasone (1 mg/mL), and Group 3 placebo, both preoperatively and postoperatively. Additionally, all patients received combined topical steroid and antibiotic drops (dexamethasone, neomycin and polymyxin B) 3 weeks postoperatively. On the day of the surgery, aqueous humour samples (0.1–0.2 mL) were obtained and IL-6 concentrations were analysed. Central foveal subfield thickness (CFT) measured using spectral-domain optical coherence tomography (SD-OCT) was analysed preoperatively and postoperatively. Results: There was no significant difference in IL-6 concentrations between groups. Postoperative CFT was significantly lower in the dexamethasone group compared to the placebo group. In addition, the correlation between IL-6 and CFT was statistically significant in the dexamethasone group. No patient developed PCME in any of the three groups. No adverse events were reported during the study. Conclusion: Topical bromfenac and dexamethasone have no significant effect on intraocular IL-6 concentration in patients with NPDR. Topical bromfenac is not more effective than topical dexamethasone in reducing postoperative CFT in patients with NPDR.
format Online
Article
Text
id pubmed-9694649
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96946492022-11-26 Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial Jukić, Anđela Kasalica Žužul, Rajka Pavan, Josip Lovrić, Mila Kozmar, Ana Plavec, Davor Kuzman, Tomislav Kalauz, Miro Jukić, Tomislav Medicina (Kaunas) Article Background and Objectives: The purpose of this study was to compare the effect of topical bromfenac and dexamethasone on the intraocular concentration of interleukin 6 (IL-6) and incidence of pseudophakic cystoid macular oedema (PCME) after cataract surgery in patients with non-proliferative diabetic retinopathy (NPDR). Materials and Methods: Ninety eyes of patients with mild-to-moderate NPDR that underwent phacoemulsification cataract surgery were divided into three groups. A detailed description of the clinical study protocol is described later in paper. In short, Group 1 received topical bromfenac (0.9 mg/mL), Group 2 dexamethasone (1 mg/mL), and Group 3 placebo, both preoperatively and postoperatively. Additionally, all patients received combined topical steroid and antibiotic drops (dexamethasone, neomycin and polymyxin B) 3 weeks postoperatively. On the day of the surgery, aqueous humour samples (0.1–0.2 mL) were obtained and IL-6 concentrations were analysed. Central foveal subfield thickness (CFT) measured using spectral-domain optical coherence tomography (SD-OCT) was analysed preoperatively and postoperatively. Results: There was no significant difference in IL-6 concentrations between groups. Postoperative CFT was significantly lower in the dexamethasone group compared to the placebo group. In addition, the correlation between IL-6 and CFT was statistically significant in the dexamethasone group. No patient developed PCME in any of the three groups. No adverse events were reported during the study. Conclusion: Topical bromfenac and dexamethasone have no significant effect on intraocular IL-6 concentration in patients with NPDR. Topical bromfenac is not more effective than topical dexamethasone in reducing postoperative CFT in patients with NPDR. MDPI 2022-11-17 /pmc/articles/PMC9694649/ /pubmed/36422204 http://dx.doi.org/10.3390/medicina58111667 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jukić, Anđela
Kasalica Žužul, Rajka
Pavan, Josip
Lovrić, Mila
Kozmar, Ana
Plavec, Davor
Kuzman, Tomislav
Kalauz, Miro
Jukić, Tomislav
Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial
title Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial
title_full Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial
title_fullStr Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial
title_full_unstemmed Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial
title_short Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial
title_sort pseudophakic cystoid macular oedema (pcme) prevention in patients with non-proliferative diabetic retinopathy (npdr)—randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694649/
https://www.ncbi.nlm.nih.gov/pubmed/36422204
http://dx.doi.org/10.3390/medicina58111667
work_keys_str_mv AT jukicanđela pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial
AT kasalicazuzulrajka pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial
AT pavanjosip pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial
AT lovricmila pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial
AT kozmarana pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial
AT plavecdavor pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial
AT kuzmantomislav pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial
AT kalauzmiro pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial
AT jukictomislav pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial